Hardly anyone's heard of either of these drugmakers, but some analysts think they could be top performers.
News & Analysis: DURECT
Investors bid up the share price after the company received some bullish praise from a Wall Street pro.
Durect gets some much-needed cash after its partner Indivior received a positive nod for its schizophrenia drug.
Remoxy is the gift that keeps on giving (and not in a good way).
News that the FDA has rejected its partner's NDA submission has investors heading for the exits.
The FDA and its advisory panel give a thumbs down to three experimental drugs, while buyout mania strikes the biotech sector.
DURECT shares dropped significantly after it's told "Do not pass go" by the FDA for its surgical painkiller, posidur.
America's fastest-growing drug problem isn't what you might think. Find out how we're fighting this dangerous problem.
A phase 3 failure of a lead drug crushes shares.
A low price doesn't always mean low quality.